A Scalable, Easy-to-Deploy Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly trained personnel, and large upfront investment.
Article activity feed
-
-
SciScore for 10.1101/2020.04.20.052159: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:These limitations underscore the need for alternative methods, such as CRISPR-based detection, to relieve some of the strain on the global supply chain for testing reagents. These state-of-the-art methods are scalable, do not …
SciScore for 10.1101/2020.04.20.052159: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:These limitations underscore the need for alternative methods, such as CRISPR-based detection, to relieve some of the strain on the global supply chain for testing reagents. These state-of-the-art methods are scalable, do not entail specialized instrumentation, and require very little specialized training. We designed CREST to capitalize on the strengths of both RT-qPCR and CRISPR-based detection, while addressing their shortcomings. CREST exploits the robustness and reliability of PCR, while harnessing the combined sensitivity and convenience of a coupled transcription-detection reaction. CREST can be run, from RNA sample to result, with no need for AC power or a dedicated facility, with minimal handling in ∼2 hours. Because the signal saturates even at low input levels (Fig. 2B) CREST offers the added advantage of binary result interpretation, similar to lateral flow test strips, but at a fraction of the price, as it does not require the costly antibodies or antibody-conjugates needed for lateral flow immunochromatography. Finally, while purified Cas13 is not yet commercially available, we were able to purify enough protein from a 1-liter bacterial culture for more than 500,000 reactions, and we can provide aliquots of protein upon request. Increasing the potential for field deployment of Cas13 for massive POC testing will require additional optimizations, such as lyophilization. Indeed, our Cas13 master mix is not affected significantly by undergoing numerous freeze-thaw c...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
-
-